Boston Scientific (NYSE:BSX) Director David Habiger Purchases 1,042 Shares of Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger bought 1,042 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.07 per share, for a total transaction of $50,088.94. Following the purchase, the director owned 14,920 shares of the company’s stock, valued at approximately $717,204.40. This represents a 7.51% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $47.73 on Thursday. The firm has a market cap of $69.17 billion, a P/E ratio of 19.32, a PEG ratio of 1.07 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $45.72 and a 200 day moving average of $61.09.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the company earned $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in BSX. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $26,000. Main Street Financial Solutions LLC grew its stake in shares of Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC raised its holdings in shares of Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC lifted its stake in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after acquiring an additional 2,556 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on BSX shares. Canaccord Genuity Group cut their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Wells Fargo & Company cut their price target on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research note on Thursday, July 30th. UBS Group dropped their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Needham & Company LLC decreased their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.